Accelerating Breakthrough Discoveries into Medicines

Ferozrpapa from OptiKira talking in a lab

Scientists in lab examining solution

From research institutions to patients

BioMotiv is the mission-driven development company associated with The Harrington Project for Discovery & Development, a national initiative centered at University Hospitals Cleveland Medical Center. The company’s focus is accelerating breakthrough discoveries from research institutions into therapeutics for patients.

Led by experienced industry professionals

BioMotiv has a capable and connected management team, advisory board, and Board that oversee the development, funding, active management, and partnering of the portfolio of therapeutic products.

Pharmaceutical Expertise

Our leadership and portfolio teams are well-versed in translational science, with deep pharmaceutical experience having supported the advancement of numerous programs into clinical development and into the marketplace.

Deep Business Networks

Through their careers, the company’s leadership team and advisory board members have developed broad relationships in the investment and pharmaceutical industries that are available to be accessed by BioMotiv companies.

Partnered with leading companies

Working with
The Harrington Project
to bridge the Valley of Death


News

OptiKira Receives Significant Grant from ALS Association

CLEVELAND, OH – February 9, 2017 OptiKira has been awarded a $498,500 grant to support the development of their platform technology for the treatment of ALS (Lou Gehrig’s disease).  The company’s technology prevents progressive cell death and is...

Allinaire Therapeutics Receives Significant Funding

CLEVELAND, OH – January 26, 2017   Allinaire Therapeutics, a respiratory therapeutics start-up launched by BioMotiv, has recently received new investments from BioCrossroads’ Indiana Seed Fund and Indiana University’s Innovate Indiana Fund. The...